We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 388

Coherus Challenges One AbbVie Humira Patent In Four PTAB Proceedings
  • Foley & Lardner LLP
  • USA
  • July 18 2017

I’ve written previously about sequential PTAB challenges to the same patent, but the dispute between Coherus Biosciences Inc. and AbbVie


Are State-Owned Patents Immune From IPRs Under The Eleventh Amendment?
  • Foley & Lardner LLP
  • USA
  • July 18 2017

In separate non-precedential decisions issued by three different panels, the PTAB has permitted State University patent owners to invoke the Eleventh


District Court Invalidates Dietary Supplement Patents On Motion To Dismiss
  • Foley & Lardner LLP
  • USA
  • July 11 2017

The U.S. District Court for the Southern District of California invalidated several dietary supplement product and method patents as being directed


Does Amgen Have Viable State Law Claims Against Sandoz Arising From The Zarxio Biosimilar Patent Dispute?
  • Foley & Lardner LLP
  • USA
  • June 27 2017

In Sandoz Inc. v. Amgen Inc. (which you can read more about here), the Supreme Court held that 42 USC 262(l)(9)(C) sets forth the exclusive federal


Are Secret Sales Prior Art Under The AIA?
  • Foley & Lardner LLP
  • USA
  • May 9 2017

In Helsinn Healthcare S.A. V. Teva Pharmaceuticals USA, Inc., the Federal Circuit found that a publicly-announced “Supply and Purchase” agreement


Federal Circuit Finds Velcade Patent Not Obvious Under Lead Compound Analysis
  • Foley & Lardner LLP
  • USA
  • July 25 2017

In Millennium Pharmaceuticals, Inc. v. Sandoz, the Federal Circuit reversed the district court decision that invalidated one of the Orange


ANDA & Biosimilar and the Law
  • Foley & Lardner LLP
  • USA
  • July 10 2017

Welcome to Foley & Lardner’s Summer 2017 edition of ANDA & Biosimilar and the Law. In our Legal Developments section, we report on a number of


Cleveland Clinic Decision Highlights Catch-22 Of Personalized Medicine Patents
  • Foley & Lardner LLP
  • USA
  • June 20 2017

The Federal Circuit decision in Cleveland Clinic Foundation v. True Health Diagnostics LLC, strikes another blow against the patent eligibility of


Federal Circuit Emphasizes Reason In Application Of Broadest Reasonable Interpretation
  • Foley & Lardner LLP
  • USA
  • June 16 2016

As we wait for the Supreme Court decision in Cuozzo Speed Technologies, LLC v. Lee, where the Court has been asked to decide whether the USPTO Patent


Supreme Court Biosimilar Patent Dance Decision Largely Favors Biosimilars
  • Foley & Lardner LLP
  • USA
  • June 13 2017

On June 12, 2017, the Supreme Court issued a unanimous decision in Sandoz Inc. v. Amgen Inc. (No. 15-1039), deciding that 42 U.S.C. 262(l)(9)(C